9 results
The primary objective of this study is to evaluate whether surgery of residual disease in patients iwth advanced GIST responding to Imatinib improves the progression free survival.The secondary objective is to correlate the pharmacokinetics of…
The purpose of the study is to investigate to what extent FE 201836 is tolerated. It will also be investigated how quickly and to what extent FE 201836 is absorbed and eliminated from the body (this is called pharmacokinetics). Also the effect on…
The purpose of the study is to investigate to what extent FE 202217 is tolerated. It will also be investigated how quickly and to what extent FE 202217 is absorbed and eliminated from the body (this is called pharmacokinetics). Also the effect on…
Our aim is to assess the sequential response of different endothelial markers following DDAVP administration. This information will be used to expand the population PK model and may enhance our insight in the mechanisms underlying the DDAVP response…
REMAP-CAP: The goal of the study is to investigate the best treatment regime for pneumonia patients. For non-pandemic pneumonia (including Influenza) we investigate this in critically ill patients. For pneumonia caused by SARS-CoV-2, we investigate…
As of protocol Amendment 06, evaluation of the safety profile of MLN9708 and/or other study medication is the only endpoint being assessed. All other study endpoints will no longer be assessed.
Study ObjectivesPrimary:• To determine the effect of ixazomib maintenance therapy on progression-free survival (PFS), compared to placebo, in patients with NDMM who have had a response (complete response [CR], very good partial response [VGPR], or…
To determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression-freesurvival (PFS) in patients with relapsed and/or refractory multiple myeloma (RRMM) The objective has been met.…
General aim; To dertemine if an alternating regimen of imatinib and regorafenib has sufficient activity and safety to warrant further evaluation as a first line treatment for metastatic GIST.